stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) EPS (diluted)
Sotera Health Company's EPS (diluted) for fiscal 2025 was $0.27, up 68.8% from $0.16 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.60. Over the past ten years it has ranged from −$0.83 (fiscal 2022) to $0.41 (fiscal 2021); the current reading is higher than 88% of that period. Sotera Health Company ranks 20th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.27 | 68.75% |
| FY2024 | $0.16 | (11.11%) |
| FY2023 | $0.18 | — |
| FY2022 | −$0.83 | — |
| FY2021 | $0.41 | — |
| FY2020 | −$0.16 | — |
| FY2019 | −$0.09 | — |
| FY2018 | −$0.03 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.20 | 6.26% |
| Jun 2026 | $0.19 | 111.11% |
| Mar 2026 | $0.09 | (25.00%) |
| Dec 2025 | $0.12 | (29.41%) |
| 24 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CDNA CareDx, Inc. compare | $2.39 |
| QGEN QIAGEN N.V. compare | $1.95 |
| VCYT Veracyte, Inc. compare | $1.55 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| SHC Sotera Health Company | $0.60 |
| NEO NeoGenomics, Inc. compare | −$0.25 |
| RDNT RadNet, Inc. compare | −$0.27 |
| ADPT Adaptive Biotechnologies Corporation compare | −$0.45 |
| GRAL GRAIL, Inc. compare | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SHC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement